Endophthalmitis Associated with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy Injections in An Office Setting

American Journal of Ophthalmology

Volumn 145, Issue 5, 2008, Pages 879-882

  Pilli, Suman ^a,b   Kotsolis, Athanasios ^a   Spaide, Richard F ^a   Slakter, Jason ^a   Freund, K Bailey ^a   Sorenson, John ^a   Klancnik, James ^a   Cooney, Michael ^a  

^a VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

^b FRIMLEY PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; PEGAPTANIB; POVIDONE IODINE; RANIBIZUMAB; VASCULOTROPIN ANTIBODY;

AGED; ARTICLE; CASE REPORT; CONFIDENCE INTERVAL; ENDOPHTHALMITIS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PREMEDICATION; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; ENDOPHTHALMITIS; EYE INFECTIONS; HUMANS; INCIDENCE; INJECTIONS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 43049101583     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2007.12.036     Document Type: Article

References (15)

1. Scott I.U., and Flynn Jr. H.W. Reducing the risk of endophthalmitis following intravitreal injections. Retina 27 (2007) 10-12
2. Aiello L.P., Brucker A.J., Chang S., et al. Evolving guidelines for intravitreous injections. Retina 25 (2005) 949-950
3. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
4. Brown D.M., Kaiser P.K., Michels M., et al., ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
5. Rosenfeld P.J., Brown D.M., Heier J.S., et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
6. Speaker M.G., Milch F.A., and Shah M.K. Role of external bacterial flora in pathogenesis of of acute postoperative endophthalimitis. Ophthalmology 98 (1991) 639-649
7. King-Smith P.E., Fink B.A., Hill R.M., Koelling K.W., and Tiffany J.M. The thickness of the tear film. Curr Eye Res 29 (2004) 357-368
8. Apt L., Isenberg S., Yoshimori R., and Paez J. Chemical preparation of the eye in ophthalmic surgery III: effect of povidone-iodine on the conjunctiva. Arch Ophthalmol 102 (1984) 728-729
9. Pansell T., Porsblad M., and Abdi S. The effect of vertical gaze position on ocular tear film stability. Clin Exp Optom 90 (2007) 176-181
10. Grimes S., Mein C., and Trevino S. Preoperative antibiotic and povidone-iodine preparation of the eye. Ann Ophthalmol 23 (1991) 263-266
11. Isenberg S., Apt L., Yoshimori R., and Khwarg S. Chemical preparation of the eye in ophthalmic surgery IV: comparison of povidone-iodine on the conjunctiva with a prophylactic antibiotic. Arch Ophthalmol 103 (1985) 1340-1342
12. Ta C.N., Egbert P.R., Singh K., et al. Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacin prophylaxis for cataract surgery. Ophthalmology 109 (2002) 2036-2041
13. Osher R.H., Amdahl L.D., and Cheetham J.K. Antimicrobial efficacy and aqueous humor concentration of preoperative and postoperative topical trimethoprim/polymyxin B sulfate versus tobramycin. J Cataract Refract Surg 20 (1994) 3-8
14. Letter to Physicians. http://www.gene.com/gene/features/avastin/letter-to-physicians.html Accessed: December 22, 2007
15. Kastango E.S., and American Society of Health-System Pharmacists (ASHP). Blueprint for implementing USP Chapter 797 for compounding sterile preparations. Am J Health Syst Pharm 62 (2005) 1271-1288